WTB
IOVA icon

Washington Trust Bank’s Iovance Biotherapeutics IOVA Stock Holding History

Washington Trust Bank’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-57
Closed – – 819
2016
Q4 		$0 Hold
57
– – ﹤0.01% 1063
2016
Q3 		$0 Buy
+57
New +$482 ﹤0.01% 1140

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Washington Trust Bank's IOVA Position: Q1 2017 in Review

Washington Trust Bank sold out of Iovance Biotherapeutics (IOVA) in Q1 2017, closing a stake of 57 shares.

Washington Trust Bank first reported a position in IOVA in Q3 2016 and held it in 2 quarters. The position peaked at $0 in Q4 2016. 81 funds tracked by Wall St. Rank hold IOVA as of Q1 2017.

  • Washington Trust Bank reported no remaining Iovance Biotherapeutics position as of Q1 2017 after selling out during the quarter.
  • Washington Trust Bank sold 57 Iovance Biotherapeutics shares in Q1 2017.
  • Washington Trust Bank first reported a position in Iovance Biotherapeutics in Q3 2016 and held it in 2 quarters.
  • Washington Trust Bank's Iovance Biotherapeutics position peaked at $0 in Q4 2016.
  • 81 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2017.

Based on Washington Trust Bank's 13F filing for Q1 2017, filed 18 Apr 2017.